TABLE 1

Clinical characteristics of the study cohorts

Finland and SwedenSweden
Finland
Spain
U.S.
Singapore
DGI (ref. 1)MDC-CC (ref. 13)MPP (ref. 16)NORDIL (ref. 18)Skania Diabetes 2000 Registry (ref. 19)Botnia-PPPFINRISK97ValenciaDallas Heart Study
GOLDN (ref. 24)BPRHS (refs. 25,26)NHS-98 (refs. 27, 28)
BlacksHispanicsWhitesChineseMalaysAsian Indians
n2,9305,50617,0375,1522,7773,4958,1911,6081,8256011,0431,0628372,691734548
n (men/women)1,448/1,4822,282/3,22410,927/6,1102,567/2,5851,583/1,0751,663/1,8414,082/4,109760/848770/1,055251/350500/543506/556225/6121,227/1,464353/381262/286
Age (years)62 ± 1158 ± 646 ± 760 ± 763 ± 1149 ± 1648 ± 1342 ± 1445 ± 1040 ± 945 ± 1049 ± 1658 ± 738 ± 1239 ± 1341 ± 12
BMI (kg/m2)28 ± 426 ± 424 ± 328 ± 430 ± 526 ± 427 ± 526 ± 532 ± 831 ± 729 ± 728 ± 632 ± 823 ± 426 ± 525 ± 5
Triglycerides (mg/dl)144 ± 101122 ± 71117 ± 71159 ± 108231 ± 275116 ± 71133 ± 92112 ± 66107 ± 95151 ± 130139 ± 107135 ± 85159 ± 99120 ± 72143 ± 87145 ± 83
HDL (mg/dl)49 ± 1553 ± 1453 ± 2144 ± 1354 ± 1451 ± 1152 ± 1546 ± 1148 ± 1547 ± 1345 ± 1255 ± 1450 ± 1344 ± 12
LDL (mg/dl)145 ± 51161 ± 38160 ± 43137 ± 40134 ± 36131 ± 36105 ± 37107 ± 33108 ± 34131 ± 34122 ± 31108 ± 35150 ± 42143 ± 40
fB-glucose (mg/dl)121 ± 4993 ± 2588 ± 1396 ± 28189 ± 6984 ± 1596 ± 24105 ± 49106 ± 4398 ± 34101 ± 18124 ± 54101 ± 24109 ± 39111 ± 38
HOMA (mmol × mU)1.7 ± 1.42.0 ± 2.73.6 ± 2.61.8 ± 1.32.4 ± 2.22.8 ± 2.5
Type 2 diabetes (%)49.98.40.08.7100.03.85.43.914.212.06.67.635.72.24.58.4
  • Data are means ± SD (continuous measures). To convert the values to millimoles per liter, multiply triglycerides by 0.01129, HDL and LDL by 0.02586, and fasting blood glucose (fB-glucose) by 0.0556. BPRHS, Boston Puerto Rican Health Study.